Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Seamless assembly of recombinant adenoviral genomes from high-copy plasmids.

Miciak JJ, Hirshberg J, Bunz F.

PLoS One. 2018 Jun 27;13(6):e0199563. doi: 10.1371/journal.pone.0199563. eCollection 2018.

2.

Understanding the pluses of pulses.

Miciak J, Bunz F.

Cell Cycle. 2017 Jul 18;16(14):1325. doi: 10.1080/15384101.2017.1337979. Epub 2017 Jun 21. No abstract available.

3.

Tumor-associated APE1 variant exhibits reduced complementation efficiency but does not promote cancer cell phenotypes.

Illuzzi JL, McNeill DR, Bastian P, Brenerman B, Wersto R, Russell HR, Bunz F, McKinnon PJ, Becker KG, Wilson DM 3rd.

Environ Mol Mutagen. 2017 Mar;58(2):84-98. doi: 10.1002/em.22074. Epub 2017 Feb 9.

4.

Long story short: p53 mediates innate immunity.

Miciak J, Bunz F.

Biochim Biophys Acta. 2016 Apr;1865(2):220-7. doi: 10.1016/j.bbcan.2016.03.001. Epub 2016 Mar 4. Review.

5.

Pathways to chromothripsis.

Ivkov R, Bunz F.

Cell Cycle. 2015;14(18):2886-90. doi: 10.1080/15384101.2015.1068483. Epub 2015 Jul 15.

6.

Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.

Larsen AR, Bai RY, Chung JH, Borodovsky A, Rudin CM, Riggins GJ, Bunz F.

Mol Cancer Ther. 2015 Jan;14(1):3-13. doi: 10.1158/1535-7163.MCT-14-0755-T. Epub 2014 Nov 5.

7.

A PTCH1 homolog transcriptionally activated by p53 suppresses Hedgehog signaling.

Chung JH, Larsen AR, Chen E, Bunz F.

J Biol Chem. 2014 Nov 21;289(47):33020-31. doi: 10.1074/jbc.M114.597203. Epub 2014 Oct 8.

8.

Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.

Bai RY, Staedtke V, Rudin CM, Bunz F, Riggins GJ.

Neuro Oncol. 2015 Apr;17(4):545-54. doi: 10.1093/neuonc/nou234. Epub 2014 Sep 24.

9.

Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction.

Li J, Ma W, Wang PY, Hurley PJ, Bunz F, Hwang PM.

Free Radic Biol Med. 2014 Aug;73:270-7. doi: 10.1016/j.freeradbiomed.2014.05.022. Epub 2014 Jun 2.

10.

A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene.

Cui Y, Hausheer F, Beaty R, Zahnow C, Issa JP, Bunz F, Baylin SB.

Cancer Res. 2014 Jul 15;74(14):3834-43. doi: 10.1158/0008-5472.CAN-13-2287. Epub 2014 May 29.

11.

Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans.

Weige CC, Birtwistle MR, Mallick H, Yi N, Berrong Z, Cloessner E, Duff K, Tidwell J, Clendenning M, Wilkerson B, Farrell C, Bunz F, Ji H, Shtutman M, Creek KE, Banister CE, Buckhaults PJ.

Mol Cancer Res. 2014 Jul;12(7):1029-41. doi: 10.1158/1541-7786.MCR-13-0286-T. Epub 2014 Apr 17.

13.

Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil.

Harris DR, Mims A, Bunz F.

Cancer Biol Ther. 2012 Nov;13(13):1319-24. doi: 10.4161/cbt.21792. Epub 2012 Aug 16.

14.

Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cancer cells.

Wilsker D, Chung JH, Bunz F.

Cell Cycle. 2012 Apr 15;11(8):1564-72. doi: 10.4161/cc.19944. Epub 2012 Apr 15.

15.

Targeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survival.

Wilsker D, Chung JH, Pradilla I, Petermann E, Helleday T, Bunz F.

Mol Cancer Ther. 2012 Jan;11(1):98-107. doi: 10.1158/1535-7163.MCT-11-0675. Epub 2011 Nov 14.

16.

Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.

Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, De Toni EN, Palagyi A, Eisen C, Ellwart JW, Rivera J, Rubio-Viqueira B, Hidalgo M, Bunz F, Göke B, Heeschen C.

Stem Cells. 2011 Mar;29(3):418-29. doi: 10.1002/stem.595.

17.

ATR mediates cisplatin resistance in a p53 genotype-specific manner.

Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F.

Oncogene. 2011 Jun 2;30(22):2526-33. doi: 10.1038/onc.2010.624. Epub 2011 Jan 24.

18.

Mitochondrial respiration protects against oxygen-associated DNA damage.

Sung HJ, Ma W, Wang PY, Hynes J, O'Riordan TC, Combs CA, McCoy JP Jr, Bunz F, Kang JG, Hwang PM.

Nat Commun. 2010 Apr 12;1:5. doi: 10.1038/ncomms1003.

19.

Checkpoint bypass and cell viability.

Chung JH, Zhang Y, Bunz F.

Cell Cycle. 2010 Jun 1;9(11):2102-7. Epub 2010 Jun 1.

PMID:
20505362
20.

Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance.

Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S.

Antioxid Redox Signal. 2010 Dec 1;13(11):1627-37. doi: 10.1089/ars.2010.3219. Epub 2010 Jul 13.

21.

Protein phosphatases and the dynamics of the DNA damage response.

Harris DR, Bunz F.

Cell Cycle. 2010 Mar 1;9(5):861. Epub 2010 Mar 1. No abstract available.

PMID:
20348842
22.

Cdk2 is required for p53-independent G2/M checkpoint control.

Chung JH, Bunz F.

PLoS Genet. 2010 Feb 26;6(2):e1000863. doi: 10.1371/journal.pgen.1000863.

23.

Ancient drugs, modern targets.

Bunz F.

Cancer Biol Ther. 2009 Nov;8(21):2063-4. Epub 2009 Nov 25. No abstract available.

PMID:
19783897
24.

Chk1 phosphorylation during mitosis: a new role for a master regulator.

Wilsker D, Bunz F.

Cell Cycle. 2009 Apr 15;8(8):1161-3. Epub 2009 Apr 11.

25.

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9. doi: 10.1073/pnas.0813333106. Epub 2009 Feb 18.

26.

Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.

Wilsker D, Petermann E, Helleday T, Bunz F.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20752-7. doi: 10.1073/pnas.0806917106. Epub 2008 Dec 17.

27.

RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.

Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S.

Cancer Res. 2008 Oct 1;68(19):7975-84. doi: 10.1158/0008-5472.CAN-08-1401.

28.

Deficiency of Bloom syndrome helicase activity is radiomimetic.

Horowitz DP, Topaloglu O, Zhang Y, Bunz F.

Cancer Biol Ther. 2008 Nov;7(11):1783-6. Epub 2008 Nov 4.

29.

Epitope tagging of endogenous genes in diverse human cell lines.

Kim JS, Bonifant C, Bunz F, Lane WS, Waldman T.

Nucleic Acids Res. 2008 Nov;36(19):e127. doi: 10.1093/nar/gkn566. Epub 2008 Sep 10.

30.

Thymidylate synthase and 5-fluorouracil: a cautionary tale.

Bunz F.

Cancer Biol Ther. 2008 Jul;7(7):995-6. Epub 2008 Jun 4. No abstract available.

PMID:
18698159
31.

Genetic knockouts and knockins in human somatic cells.

Rago C, Vogelstein B, Bunz F.

Nat Protoc. 2007;2(11):2734-46.

PMID:
18007609
33.

Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.

Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE.

Cancer Biol Ther. 2007 May;6(5):654-60. Epub 2007 Feb 7.

PMID:
17387268
34.

ATM and ATR: components of an integrated circuit.

Hurley PJ, Bunz F.

Cell Cycle. 2007 Feb 15;6(4):414-7. Epub 2007 Feb 19. Review.

PMID:
17312392
35.

Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation.

Hurley PJ, Wilsker D, Bunz F.

Oncogene. 2007 Apr 19;26(18):2535-42. Epub 2006 Oct 16.

PMID:
17043640
36.

p53 regulates mitochondrial respiration.

Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM.

Science. 2006 Jun 16;312(5780):1650-3. Epub 2006 May 25.

37.

Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.

Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH.

Cancer Res. 2006 Feb 1;66(3):1684-936.

38.

Improved methods for the generation of human gene knockout and knockin cell lines.

Topaloglu O, Hurley PJ, Yildirim O, Civin CI, Bunz F.

Nucleic Acids Res. 2005 Oct 7;33(18):e158.

40.

Digital HLA allelotyping.

Topaloglu O, Civin CI, Bunz F.

Cancer Biol Ther. 2004 Sep;3(9):899-902. Epub 2004 Sep 15.

PMID:
15326386
42.
43.

Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria.

Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, Agrawal N, Borzillary S, McCaffery JM, Watson EL, Lin KS, Bunz F, Baidoo K, Pomper MG, Kinzler KW, Vogelstein B, Zhou S.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15083-8. Epub 2003 Dec 1.

44.

The Chk2 tumor suppressor is not required for p53 responses in human cancer cells.

Jallepalli PV, Lengauer C, Vogelstein B, Bunz F.

J Biol Chem. 2003 Jun 6;278(23):20475-9. Epub 2003 Mar 24.

45.

High-throughput sequencing and cancer genetics.

Bunz F.

Cell Cycle. 2002 Sep-Oct;1(5):320-1. No abstract available.

PMID:
12461293
46.

Targeted inactivation of p53 in human cells does not result in aneuploidy.

Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, Vogelstein B, Lengauer C.

Cancer Res. 2002 Feb 15;62(4):1129-33.

47.

Human cell knockouts.

Bunz F.

Curr Opin Oncol. 2002 Jan;14(1):73-8. Review.

PMID:
11790984
48.

Cell death and cancer therapy.

Bunz F.

Curr Opin Pharmacol. 2001 Aug;1(4):337-41. Review.

PMID:
11710730
49.

Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.

Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B.

Nat Med. 2001 Oct;7(10):1111-7. Erratum in: Nat Med 2001 Nov;7(11):1255.

50.

Securin is required for chromosomal stability in human cells.

Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM, Kinzler KW, Vogelstein B, Lengauer C.

Cell. 2001 May 18;105(4):445-57.

Supplemental Content

Support Center